Mark A. Goldberg
About Mark A. Goldberg
Independent director at Intensity Therapeutics (INTS) since May 2018; age 64 as of June 4, 2024. He holds a BS in Computer Science from MIT and an MD from the University of Massachusetts Medical School, with Radiology residency at Massachusetts General Hospital (Chief Resident; Harvard Medical School appointments). Former President & COO of PAREXEL; currently Chairman & CEO of Allucent and Executive Chairman of Thread. The board has affirmatively determined his independence under Nasdaq rules.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| PAREXEL International | President & COO | Through 2017 | Oversaw revenue-generating segments; scaled global infrastructure and strategic partnering model. |
| Perceptive Informatics (now PAREXEL Informatics) | Founder/Builder (technology subsidiary) | Earlier career | Established tech capabilities supporting trials. |
| Massachusetts General Hospital / Harvard Medical School | Chief Resident, Radiology; Staff physician; academic appointments | Prior to industry | Clinical leadership and academic credentials. |
External Roles
| Organization | Role | Since | Notes |
|---|---|---|---|
| Allucent | Chairman & CEO | 2019 | Global mid-sized CRO. |
| Thread | Executive Chairman | 2019 | Decentralized research and eCOA provider. |
Board Governance
- Independence: Board determined Goldberg is independent (Nasdaq definition).
- Board tenure: Director since May 2018; current term ends at the 2025 annual meeting (Class II).
- Committee assignments:
- Audit Committee: Member; Audit met 4 times in FY2023.
- Compensation Committee: Member; Compensation did not meet in FY2023.
- Nominating & Corporate Governance Committee: Chair.
- Attendance: No director attended fewer than 75% of board and applicable committee meetings in FY2023.
- Board leadership: CEO serves as Chair; no Lead Independent Director; independent directors meet without CEO as needed.
Fixed Compensation
| Year | Component | Amount |
|---|---|---|
| 2023 | Cash fees earned | $26,750 |
| Policy (current) | Board annual retainer (non-employee) | $40,000 |
| Policy (current) | Audit Committee: Chair / Member | $20,000 / $10,000 |
| Policy (current) | Compensation Committee: Chair / Member | $15,000 / $7,000 |
| Policy (current) | Nominating Committee: Chair / Member | $10,000 / $5,000 |
Notes:
- No meeting fees; reasonable expenses reimbursed; fees paid quarterly in arrears.
Performance Compensation
| Year | Equity Awards | Performance Metrics | Notes |
|---|---|---|---|
| 2023 | None awarded to non-employee directors | Not disclosed | Company did not grant equity to directors in 2023. |
Other Directorships & Interlocks
| Company | Type | Role | Interlock/Conflict Note |
|---|---|---|---|
| Allucent | Private CRO | Chairman & CEO | No related-party transactions disclosed with INTS. |
| Thread | Private (tech/eCOA) | Executive Chairman | No related-party transactions disclosed with INTS. |
- Related-party transactions on INTS’ board involve Daniel Donovan’s rareLife Solutions ($132,400 publications services); Goldberg not listed as a party.
Expertise & Qualifications
- Clinical and technical: MD (Radiology), Chief Resident at MGH; technology leadership (Perceptive/PAREXEL Informatics).
- CRO/operator experience: Senior roles scaling global operations and strategic partnerships at PAREXEL.
- Governance: Committee experience across audit, compensation, and nomination; chair of nominating.
- Education: BS (MIT); MD (UMass).
Equity Ownership
| Metric | As of May 31, 2024 | As of Aug 31, 2025 |
|---|---|---|
| Beneficial ownership (shares) | 81,500 (<1%) | 119,000 (<1%) |
| Vested/exercisable options within 60 days | 81,500 | 119,000 |
| Unvested/unexercisable options | 56,250 | 68,750 |
| Shares outstanding reference | 13,711,877 | 49,055,462 |
Notes:
- Percent ownership as disclosed is less than 1% in both periods.
Governance Assessment
-
Strengths:
- Independent status with deep CRO and clinical background; chairs nominating and serves on audit and compensation.
- Attendance above threshold in FY2023; audit committee active.
- No disclosed related-party transactions, pledging, or hedging involving Goldberg.
-
Watch items / red flags:
- No Lead Independent Director; combined CEO/Chair structure concentrates power; rely on executive sessions to mitigate.
- Compensation Committee did not meet in 2023, suggesting limited formal oversight cadence during that year.
- Company-level listing risk and capital structure actions (reverse split authorization) signal broader governance and market-risk context; board’s discretion to effect reverse split within 1-for-5 to 1-for-30 range.
Overall, Goldberg’s credentials and independence support board effectiveness in oversight and governance, with committee leadership on nominations and participation on audit/compensation aligning with investor expectations; absence of personal conflicts is positive. The lack of a Lead Independent Director and limited compensation committee activity in 2023 merit continued monitoring.